Medicare AdvantageCoverageMedium impact
MA08.016h, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Cardiology, Pulmonology, Internal Medicine·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a reissued policy (effective 04/01/2026) governing coverage and billing for pharmacologic treatment of pulmonary artery hypertension (PAH) using intravenous, subcutaneous, and inhaled agents. The billing team must review the specific coverage criteria, prior authorization requirements, and approved medication codes to ensure compliant claim submission for PAH patients.
Action Required
By March 15, 2026: Billing team must obtain and review the complete MA08.016h policy text from the provided URL to identify: (1) specific HCPCS codes for IV, subcutaneous, and inhaled PAH medications; (2) prior authorization requirements and thresholds; (3) medical necessity documentation requirements. Update billing system rules and encounter templates accordingly. Communicate any prior auth workflow changes to providers and front desk staff. All PAH-related claims submitted on or after April 1, 2026 must comply with the reissued policy or face denial.